Breast Cancer Prevention: Time for Change
Rowan T Chlebowski1, Aaron K Aragaki2, Kathy Pan1
1Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA.
JCO Oncology Practice
|July 28, 2021
Summary
Current breast cancer prevention strategies, like tamoxifen, don't reduce deaths. New approaches are needed to effectively lower breast cancer mortality and improve survival rates.
Area of Science:
- Oncology
- Preventive Medicine
- Clinical Trials
Background:
- Established breast cancer prevention guidelines have remained static for two decades.
- Endocrine-targeted agents, such as tamoxifen, raloxifene, and aromatase inhibitors, primarily prevent estrogen receptor (ER)-positive, progesterone receptor (PR)-positive breast cancers.
- These agents have not demonstrated a reduction in breast cancer-related mortality, despite preventing certain cancer subtypes.
Purpose of the Study:
- To evaluate the effectiveness of current breast cancer prevention strategies in reducing mortality.
- To investigate alternative approaches for breast cancer risk reduction, particularly for subtypes with inferior survival rates.
- To determine if specific interventions can decrease deaths from breast cancer.
Main Methods:
- Analysis of three tamoxifen placebo-controlled prevention trials (N=23,360) to assess tamoxifen's impact on breast cancer incidence and mortality.
- Examination of data from the Women's Health Initiative Dietary Modification trial (N=48,835) focusing on ER-positive, PR-negative cancers and breast cancer deaths.
- Review of findings from the Women's Health Initiative trial on conjugated equine estrogen (N=10,739) regarding ER-positive, PR-negative cancers and mortality.
Main Results:
- Tamoxifen trials showed 226 fewer breast cancer cases but nine more deaths.
- The Women's Health Initiative Dietary Modification trial found a significant reduction in ER-positive, PR-negative cancers (HR, 0.77) and a 21% decrease in breast cancer deaths.
- The Women's Health Initiative conjugated equine estrogen trial demonstrated a significant reduction in ER-positive, PR-negative cancers (HR, 0.44) and a 40% decrease in breast cancer deaths.
Conclusions:
- Current endocrine-targeted agents may not be effective in reducing overall breast cancer mortality.
- ER-positive, PR-negative breast cancers and triple-negative cancers exhibit poorer survival rates.
- Interventions in the Women's Health Initiative trials suggest potential for reducing specific breast cancer subtypes and associated mortality, warranting a reevaluation of prevention strategies.
Related Concept Videos
02:59Cancer Prevention
7.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.0K
01:30Preventive Healthcare Services
1.2K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
1.2K
01:22Healthcare Associated Infections II: Preventive Measures
3.2K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.2K
01:26Levels of Health Promotion and Illness Prevention
13.8K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
In primary prevention, actions taken before disease onset prevent the disease from...
13.8K
01:30Cancer Vaccines
581
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
581
01:21Cancer Survival Analysis
481
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481